Dr. Liu received her Ph.D. from Chinese Academy of Sciences in 2014 and is currently continuing her post-doctoral research at Brigham and Women’s Hospital (BWH), Harvard Medical School (HMS). She has extensive experience in the research fields of nanomedicine and biomaterials, and has developed many multifunctional nanomaterials for cancer imaging and therapy. Dr. Liu is currently developing innovative theranostic biomaterials and nanotechnologies for safe and effective delivery of biomacromolecules (e.g. siRNA) and small molecular drugs for imaging-guided therapy of diseases such as cancer and stroke.
Dr. Mohammad Ariful Islam obtained his Bachelor in Biotechnology and Genetic Engineering from the University of Development Alternative, Bangladesh in 2007. He earned his Master (Feb 2010) and Doctoral degree (Feb 2013) from Seoul National University, South Korea. He developed a number of smart polymeric carriers to deliver genes (DNA, siRNA, microRNA) for cancer therapy and subunit antigens for vaccine therapy. Dr. Islam achieved several research awards including “Brain Korea 21 2012); the “Best Young Scientist” (2013); the ‘Research Excellence Award’ (2013) from Seoul National University. He has authored about 30 peer-reviewed Articles as well as Book Chapters (as far as 2016) and few of his research works have been issued/pending national and international patents. Currently, he is a Postdoctoral Fellow in the Farokhzad Lab at Harvard Medical School and Brigham & Women’s Hospital (HMS/BWH) since March 2014, where he has been working on developing mRNA nanotherapeutics for cancer immunotherapy, gene therapy as well as asthma nanotherapeutics.
Dr. Phei Er Saw is a post-doctoral fellow in the Farokhzad Lab at Harvard Medical School (HMS) and Brigham and Women’s Hospital (BWH). She received her Ph.D. in the Department of Biological Sciences in Korea Advanced Institute of Science and Technology (KAIST) for her research work on bio-nanomedicine in South Korea (2014). She then served as postdoctoral fellow in the Department of Biological Sicences, KAIST (March 2014 –May 2015) and is currently continuing her post-doctoral research in the Laboratory of Nanomedicine and Biomaterials at HMS (2015-2016). She currently leads several projects aimed at the development of multi-stage targeted nanoparticles encapsulating small-biologic drug conjugates, lipid-based novel nanomaterials for various applications and natural-product based nanoparticle for cancer therapy.
Sejin Son received her Ph.D. at the Department of Chemistry, Pohang University of Science and Technology (POSTECH). She worked as a postdoctoral fellow in the Center for Theragnostics at Korea Institute of Science and Technology (KIST). Currently, Dr. Son is employed at Harvard Medical School (HMS) and Brigham and Women’s Hospital (BWH) as a postdoctoral fellow. She has been developing versatile smart nano-biomaterials for drug/gene/vaccine delivery, ultrasound contrast agents, and specific immune-cell targeting systems. Her wide range of therapeutic applications include combating and imaging of various cancers, ocular and inflammation-related diseases. She is now extending her research background from academic to translational nanomedicine as works with Dr. Omid Farokhzad in the Laboratory of Nanomedicine and Biomaterials.
Dr. Ki Su Kim received B. S. and Ph.D. in Materials Science and Engineering in Pohang University of Science and Technology (POSTECH) in Republic of Korea. And he worked as Research Fellow at Harvard Medical School (HMS) and Wellman Center for Photomedicine at Massachusetts General Hospital (MGH). He is currently a Postdoctoral Research Fellow in the Farokhzad Lab and Harvard Medical School (HMS) and Brigham Women’s Hospital (BWH). He carried out many researches on biomaterials engineering for biomedical applications, such as drug delivery, photomedicine, bioimaging and biosensors with in vivo animal model, and published over 30 research papers, book chapters and over 10 US and international patent grants/applications. Dr. Kim is currently developing bioimaging technique for investigating behavior and therapeutic mechanism of nano-therapeutics in cancer, and non-invasive drug delivery system.
Dr. Wei Tao is a Postdoctoral Research Fellow in the Farokhzad Lab at Harvard Medical School and Brigham and Women’s Hospital. He received his BE degree in Biomedical Engineering (2011) from Huazhong University of Science and Technology and PhD degree in Biology (2015) from Tsinghua University. During his PhD study, he also attended Harvard University as a visiting PhD student (2014). He has authored over 30 papers that published on Adv Mater, Angew Chem, PNAS, Theranostics, Biomaterials and so on. Dr. Wei Tao has also received awards such as Tsinghua-“Ling Feng” Instructor Award (2015), Student Fellowship from World Pharma Congress (2014), National Scholarship from Ministry of Education of the People’s Republic of China (2012, 2014), Hong Kong Qiu Shi Science and Technologies Foundation Award (2010) and so on. His current research interest is nanomaterials for drug delivery and bioimaging.
Dr. Parisa Abadi is an NIH postdoctoral research fellow in the Farokhzad lab. She explores the biomedical applications of nanomaterials and probes the role of mechanics in tissue engineering, drug delivery, and medical devices. She received her Ph.D. degree in Mechanical Engineering from Georgia Institute of Technology in 2013 with a focus on mechanics and engineering applications of nanomaterials. Prior to that, she received her M.S. degree in Mechanical Engineering from the State University of New York at Buffalo and B.S. degree in Aerospace Engineering from Sharif University of Technology. In 2013-2014, she was a Visiting Assistant Professor in the Department of Mechanical Engineering at Stevens Institute of Technology where she served as a research advisor for graduate and undergraduate students and also taught engineering courses. You can learn more about her here.
Dr. Claudia Corbo received her PhD degree in Molecular Oncology at the European School of Molecular Medicine (www.semm.it), joint between the University of Naples “Federico II” and University of Milan, in 2012. She did her first post-doctoral training in the research organization CEINGE, Advanced Biotechnologies (Naples, Italy) where her research was mainly devoted on the discovery of tumor biomarkers by means of proteomic and mass spectrometry. In 2013, she joined the Center for Biomimetic Medicine at the Houston Methodist Research Institute (Houston, TX) to perform her second post-doc. Her research was focused on understanding events at the nano–bio interface, with particular focusing on bio-inspired nanoparticles. She currently holds a postdoctoral fellowship at Brigham and Women’s Hospital, Harvard Medical School. She is working on protein corona formation and nanoparticle/cell interaction to explore possible novel nano-therapeutic cancer applications.
Dr. Shahed Behzadi received his Ph.D. from Max Planck Institute for Polymer Research (MPI-P) in 2016 and he currently holds a postdoctoral fellowship position at Brigham and Women’s Hospital (BWH), Harvard Medical School (HMS). The main subject of his doctoral project was to develop advanced stimuli-responsive organic and inorganic nanocapsules with enhanced capabilities for selective-release of payloads. Dr. Behzadi is currently developing cutting-edge nanotechnology drug delivery systems with the ability to diagnose cancerous cells, target infecting bacteria and induce bone regeneration. The ultimate goal of his current research is to clinically translate these nanomedicines.